HCLTech launches advanced clinical trials solution with Denodo and AWS
HCLTech, a prominent global technology company, has unveiled a cutting-edge clinical trials and diagnosis solution developed in collaboration with Denodo, a leader in data management, ... Read More
FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C
In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement from the U.S. Food and Drug Administration ... Read More
$35 million boost for Rona Therapeutics: A new era in RNA medicine begins!
Rona Therapeutics, a clinical-stage company leading the way in nucleic acid drug research and development, has successfully completed a Series A+ financing round, raising $35 ... Read More
Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More
Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application ... Read More
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More
Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage ... Read More
hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More